References
- Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist 2004;9:406–416.
- Good DJ, Gascoyne RD. Atypical lymphoid hyperplasia mimicking lymphoma. Hematol Oncol Clin North Am 2009;23:729–745.
- Hicks J, Flaitz C. Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Pediatr Otorhinolaryngol 2002;65:195–202.
- Ferry JA, Zukerberg LR, Harris NL. Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin's disease. Am J Surg Pathol 1992;16:252–258.
- Jones D. Dismantling the germinal center: comparing the process of transformation, regression, and fragmentation of the lymphoid follicle. Adv Anat Pathol 2002;9:129–138.
- Nguyen PL, Ferry JA, Harris NL. Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study. Am J Surg Pathol 1999;23:27–33.
- Hansmann ML, Felbaum C, Hui PK, . Progressive transformation of germinal centers with and without association to Hodgkin's disease. Am J Clin Pathol 1990;93:219–226.
- Brauninger A, Yang W, Wacker H-H, . B-cell development in progressively transformed germinal centers: similarities and differences compared with classical germinal centers and lymphocyte-predominant Hodgkin disease. Blood 2001;97:714–719.
- Kojima M, Nakamura S, Motoori T, . Progressive transformation of germinal centers: a clinicopathological study of 42 Japanese patients. Int J Surg Pathol 2003;11:101–107.
- Vidal L, Gafter-Gvili A, Leibovici L, . Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248–255.
- Solal-Céligny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30:S16–S21.
- Harris NL, Jaffe ES, Diebold J, . Lymphoma classification: from controversy to consensus – the REAL and WHO classification of lymphoid neoplasms. Ann Oncol 2000;11:3–10.
- Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989;7:1630–1636.
- Juweid ME, Stroobants S, Hoekstra OS, . Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
- Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
- Picardi M, De Renzo A, Pane F, . Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48: 1721–1727.
- Picardi M, Soricelli A, Grimaldi F, . Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 2011;22:671–680.
- Tzankov A, Krugmann J, Fend F, . Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res 2003;9:1381–1386.
- Picardi M, Gennarelli N, Ciancia R, . Randomized comparison of power Doppler ultrasound-directed excisional biopsy with standard excisional biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. J Clin Oncol 2004;22:3733–3740.
- Eng J. Sample size estimation: how many individuals should be studied? Radiology 2003;227:309–313.
- Chang CC, Osipov V, Wheaton S, . Follicular hyperplasia, follicular lysis, and progressive transformation of germinal centers. A sequential spectrum of morphologic evolution in lymphoid hyperplasia. Am J Clin Pathol 2003;120:322–326.
- Younes A, Fayad LY, Goy A, . Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups. Blood 2006; 108(Suppl. 1): Abstract 2742.
- Schulz H, Rehwald U, Morschhauser F, . Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109–111.
- Maeda LS, Advani RH. The emerging role of rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 2009;21:397–400.
- Deconinck E, Miadi-Fargier H, Pen CL, . Cost-effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeco-nomics 2010;28:35–46.
- McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712–720.
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.